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The delivery of bioactive molecules directly to damaged tissues represents a technological challenge. We propose here a new system
based on virus-like particles (VLP) from rotavirus, with a marked tropism for the gut to deliver bio-active molecules to intestinal
cells. For this, nonreplicative VLP nanoparticles were constructed using a baculovirus expression system and used to deliver an
exogenous biomolecule, the green ﬂuorescent protein (GFP), into either MA104 cells or intestinal cells from healthy and 2,4,6-
trinitrobenzene sulfonic acid (TNBS)-treated mice. Our results show that expression of rotavirus capsid proteins in baculovirus
led to the auto assembly of VLP that display similar properties to rotavirus. In vitro experiments showed that VLP were able to
enter into MA104 cells and deliver the reporter protein. Intragastric administration of ﬂuorescent VLP in healthy and TNBS-
treated mice resulted in the detection of GFP and viral proteins in intestinal samples. Our results demonstrate an eﬃcient entry
of non-replicative rotavirus VLP into the epithelial cell line MA104 and provide the ﬁrst in vivo evidence of the potential of these
nanoparticles as a promising safe candidate for drug delivery to intestinal cells.
1.Introduction
Delivery systems able to eﬃciently transfer bioactive mol-
ecules to speciﬁc target tissue represent a technological
challenge. Viral vectors are under intensive investigation as
eﬃcient delivery systems to be used in clinical trials because
of their natural invasive characteristics and tropism [1, 2].
However, viral vectors lack speciﬁcity for intestinal damaged
tissuesandcoulddisplayreplicativepropertiesthatmayelicit
side-eﬀects [3]. In this context, an attractive strategy is the
elimination of the genetic material in order to turn them
into replication-defective vectors, and use only the empty
particles as nanoboxes for biomolecule delivery. Rotaviruses,
members of the Reoviridae family, exhibit a marked tropism
for the intestinal epithelium. Their capsid consists of three
concentric layers (i) the outer-most layer, which is composed
of VP7 and VP4 proteins; (ii) the inner layer composed of
trimers of VP6 protein, and (iii) the core which is mostly
composed of a nucleic acid binding protein, VP2. Coexpres-
sion of capsid viral proteins in the baculovirus expression
system leads to the production of nonreplicative rotavirus
derived virus-like particles (VLP) [4]. Several studies have
demonstrated that VLP display properties very similar to
those of rotavirus and that they lack infectivity [5–8]. Thus,
their natural tropism and nonreplicative properties make
rotavirus-derived VLP a promising safe candidate for drug
delivery to intestine in pathologies such as inﬂammatory
bowel diseases (IBD). We hypothesized that this vector must
beabletodeliverinsitu(inpathologicaltissues)therapeutics
moleculesasanti-inﬂammatoryproteinsorRNAitointerfere2 Journal of Biomedicine and Biotechnology
with the proinﬂammatory pathway of NFκB , using the same
mechanism used by Rotavirus to infect and deliver the RNA
to intestinal cells. It has been reported that heterologous
proteins as green ﬂuorescent protein (GFP) could genetically
fused to VP2 and incorporated into VLP [4]. In order to
assure the correct VLP assembly, we consider that molecules
smaller than of ∼250 amino acids could easily be integrated
into this delivery system by a fusion to VP2 protein. In the
present work, we used home-made ﬂuorescent VLP (VLP-
GFP), previously reported by Charpilienne et al. [4], which
are composed by the fusion of green ﬂuorescent protein
(GFP) to VP2 protein (GFP:VP2). We controlled their
quality and we evaluated their potential as delivery a system
to epithelial cells using both in vitro and in vivo models. To
our knowledge, this is the ﬁrst work where these biological
objects were analyzed both in vitro and in vivo with the same
VLP batches.
2.MaterialandMethods
All reagents were obtained from Sigma-Aldrich (St. Louis,
MO), unless otherwise stated.
2.1. Antibodies. We used here previously tested antibodies
against rotavirus or its structural proteins: anti-VP4 (clone
7.7) [9, 10], anti-VP2 (clone E22) [11], anti-VP6 (clone
RV138) [12], anti-VP7 (M60) [13], anti RF (clone K2) [14,
15] Rabbit polyclonal anti-RF antiserum (8148) [9].
2.2. Production and Puriﬁcation of Complete and Incomplete
VLP. Nonreplicative rotavirus-derived VLP composed of
VP2, VP4, and VP7 from bovine rotavirus RF strain and
VP6 of simian rotavirus SA11 strain were produced and
puriﬁed in our own laboratory using the baculovirus expres-
sion system as described elsewhere [4]. Brieﬂy, Sf9 insect
cells were coinfected with two recombinant baculoviruses
expressing the GFP-VP2 fusion protein and the VP6 pro-
tein to generate incomplete VLP (VLP-GFP 2/6) or four
recombinant baculoviruses expressing GFP: VP2, VP6, VP4,
and VP7 viral proteins to generate complete VLP (VLP-GFP
2/6/7/4). Viral auto-assembled proteins were collected 6 days
after infection from the Sf9 culture medium and puriﬁed by
density gradient centrifugation in CsCl. Finally the particles
wereresuspendedinTNCbuﬀer(50mMTris,150mMNaCl,
10mM CaCl2 (pH 7.5)). The characterization of VLP was
performed by Western Blot analysis and the concentration
of proteins was determined using Quantity One analysis
software (Bio-Rad Laboratories, France) and bovine serum
albumin (BSA) (Pierce, Rockford, IL) as standard. Based on
the number of molecules that compose the VLP and the
molecular weight of each protein, it was assumed that 1-
mg of VLP suspension contains ∼1.2 ×1013 particles/ml [4].
GFP protein expression was quantiﬁed in 96-well plates by
spectroﬂuorometry using TECAN SpectraFluor (excitation
ﬁlter: 485nm and emission ﬁlter: 535nm) and the light
emittedwasrecordedinarbitraryunitsusingXﬂuorSoftware
V3.21(TecanU.S.,ResearchTrianglePark,NC).Appropriate
assembly of VLP was conﬁrmed by stoichiometry analysis
and electron microscopy as previously described [4].
2.3. VLP Uptake by MA104 Cells. African green monkey
kidney cells (MA 104) were grown as previously described
[4]. For in vitro visualization, ﬂuorescent (complete and
incomplete) VLP previously treated with trypsin were incu-
batedwithMA104epithelialcellsfor1hourat4◦Cand,since
trypsin has been previously shown to be required to promote
rotavirus cell entry [16, 17], nontrypsin treated VLP were
used as control. VLP nonspeciﬁcally attached to the plasma
membrane were removed by several washes, then incubation
continued for 30 minutes at 37
◦C. After incubation, cells
were washed and ﬁxed with 2% of paraformaldehyde (PFA)
for 20 minutes at room temperature in the absence of
any detergent to prevent cell permeabilization. Cells were
washed again and incubated with a red ﬂuorescent lectin,
Wheat Germ Agglutinin (WGA) conjugated with Alexa
Fluor 594 (Molecular Probes, Invitrogen France) in order
to visualize the cell surface. Labeled cells were observed by
confocal microscopy. The total ﬂuorescence was quantiﬁed
using the built-in Leica software that allows to measure
speciﬁc-over-backgroundﬂuorescenceonadeﬁnedregionof
interest (ROI). Speciﬁcally, the ROI was deﬁned as the entire
microscopicﬁeldineachoftheﬁveindependentexperiments
and we have compared the total green ﬂuorescence at the
diﬀerent time.
2.4. In Vivo VLP Uptake by Mice Intestinal Cells. Seven
week-old male Balb/c mice were purchased from Centre
d’Elevage Ren´ e Janvier, (Le Genest Saint-Isle, France) and
were housed in groups of four mice per cage in pathogen-
free Texler-type isolators (La Calhene, Velizy, France) under
sterile conditions with water and were fed ad libitum in the
animal facilities of the Unit´ e d’Ecologie et de Physiologie
du Syst` eme Digestif at the Institut National de la Recherche
Agronomique (INRA, Jouy-en-Josas, France). Experiments
werestartedafteroneweekofacclimatizationandperformed
according to international rules of animal care. To respect
the safe volume to gavage in mice, groups of mice were
inoculated by intragastric gavage with two consecutive doses
of complete or incomplete VLP (1 × 1012 particles/ml) at 2-
hour intervals in order to allow mice to recover. TNC buﬀer
was used as a negative control. Four hours after the last
administration, mice were sacriﬁced by vertebral dislocation;
the intestine was removed under sterile conditions and cut
into regional sections: ileum, proximal colon and distal
colon. Each section was ﬂushed out with phosphate buﬀer
solution (PBS, Gibco BRL, France) as described elsewhere
[18]. For the ELISA assay, ∼2cm × 1cm pieces of tissue
sample (ileum, proximal or distal colon) were cut, washed
vigorously and placed into 1.5ml of PBS containing antipro-
teases (Protease Inhibitor Cocktail, Complete mini tablets,
Roche Diagnostics, France). The samples were homogenized
using a Polytron homogenizer and cell debris eliminated
by centrifugation; supernatants were recovered and stored
at −80
◦C. For microscopic examination, ileum and colon
samples were recovered cut longitudinally, cleaned andJournal of Biomedicine and Biotechnology 3
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Figure 1: Analysis of VLP puriﬁed from baculoviruses infected Sf9 insect cells. Incomplete and complete VLP from the culture medium
of Sf9 cells were puriﬁed using CsCl gradients. (a) Coomassie blue-stained SDS-PAGE showing incomplete and complete VLP containing
GFP:VP2 fusion proteins. (b) Western-blot of recombinant VLP proteins using either anti-VP4 or anti-RF rotavirus antibodies. M: protein
molecular weight markers. (c) Electron microscopy analysis of incomplete VLP negatively stained with a 2% uranyl acetate solution, scale
bar 100nm. Insert: higher magniﬁcation of a single VLP.
frozen in liquid nitrogen. Intestinal samples were then sliced
into 5μm sections and stored at −20
◦C until analysis.
2.5. Mouse Model of Inﬂammation. Twelve mice (colitis
group) were anaesthetized with isoﬂurane and received
intrarectally 100μl (100mg/kg) of 2,4,6-trinitrobenzene sul-
fonic acid (TNBS, Fluka, France) in 50% ethanol as previ-
ously described [19]. Twelve other mice (colitis free group)
served as na¨ ıve control. Two days after TNBS administration
in the colitis group, mice of each group were randomized
into three diﬀerent subgroups to receive complete VLP,
incomplete VLP, or TNC buﬀer as above described. After
sacriﬁce, a macroscopic evaluation of colitis damage was
performed according to the Wallace criteria [20].
2.6. ELISA. For ELISA measurements, the concentrations of
total proteins in homogenate samples from intestine were
determinedusingtheBicinchoninicacid(BCA)proteinassay
reagent (Pierce, Rockford, IL) and protein concentrations
adjusted at 100μg/ml and 400μg/ml, respectively. Ninety-
six well plates Nunc Maxisorp (Nunc, Roskilde, Denmark)
were coated with antirotavirus antibodies (see above) diluted
1:1000 in sodium carbonate buﬀer (50mM sodium car-
bonate, 1mM MgCl2 pH 9.8) and incubated overnight at
4◦C. Plates were washed twice with PBS containing 0.05%
Tween-20 (PBS-T). Wells were then blocked with blocking
buﬀer (PBS-T containing 3% bovine serum albumin) for
2 hours at room temperature and washed three times
with PBS-T. A 100μl sample previously diluted in blocking
buﬀer was added to each well and incubated 2 hours at
room temperature. After three washing steps, anti-RF rabbit
polyclonal antibody (kindly provided by Dr R. L’Haridon,
INRAJouyenJosas,France)diluted1:500inblockingbuﬀer
was added and the plate incubated for 1 hour at room
t e m p e r a t u r e .T h ep l a t e sw e r ew a s h e da sd e s c r i b e da b o v ea n d
horseradish peroxidase conjugated (HRP) goat anti-rabbit
IgG antibodies (Rockland, Gilbertsville, PA) diluted 1:5000
in blocking buﬀer was added to each well and incubated for
1 hour at room temperature. After 3 washes, the reaction
was developed by addition of 3,3 ,5,5 -tetramethylbenzidine
substrate (TBM, Sigma-Aldrich, St. Louis, MO). Finally the
reaction was stopped by the addition of H2SO4 and the
absorbance was immediately measured at 450nm.
The amount of green ﬂuorescent protein (GFP) was
assessed by ELISA using React-bind anti-GFP coated plates4 Journal of Biomedicine and Biotechnology
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Figure 2: Quantiﬁcation of VLPcarrying GFP:VP2fusion protein.
(a) CsCl puriﬁed ﬂuorescent VLP were concentrated by centrifu-
gation and the pelleted VLP recovered in TNC buﬀer, spotted on
glass slides, and visualized by confocal microscopy. TNC buﬀer was
used as a control. (b) Increasing amounts of VLP-GFP, as measured
by protein concentration, were placed in 96-well plaques and
ﬂuorescence intensity was measured by direct spectroﬂuorometry
using a TECAN SpectraFluor. Results are representative of 3
independent experiments.
(Pierce, Rockford, IL). Brieﬂy, a 100μl sample was coated for
1 hour at room temperature. Plates were washed; rabbit anti-
GFP serum (kindly provided by Dr J.-L. Delaunay, INSERM-
UPMC UMRS538, Paris, France) diluted 1:1000 in blocking
buﬀer was added and incubated for 1 hour. HRP conjugated
goat anti-rabbit, and the TBM substrate was then added as
above described.
2.7. Confocal Microscopy. Fixed MA104 cells were examined
for WGA and VLP-GFP using a Leica TCS Spectral (SP2)
instrument equipped with an inverted microscope using
63 × and 100 × oil immersion objectives. Fluorescence
intensity of VLP-GFP was quantiﬁed using on-line “Scan
Ware” software. Cryosections from mice intestines were
ﬁxed in acetone for 10 minutes, air-dried, rinsed twice with
PBS, treated with retrieval buﬀer (PBS pH 7.4 containing
0.3% Triton X-100 and 1% bovine serum albumin) and
blocked with blocking solution (PBS with 1% bovine serum
albumin). The primary rabbit anti-RF antibody was used
at 1:500. Indirect ﬂuorescence was carried out using Cy3-
conjugated goat anti-rabbit (Jackson Immunoresearch, West
Grove, PA). Double-ﬂuorescence acquisition was performed
for colocalization studies of viral proteins and GFP using
the confocal microscope. In some experiments, FITC Con-
jugated Datura stramonium (Lectin DSA, EY Laboratories
Inc.) was used as a green-ﬂuorescence positive control to
visualize the gut.
2.8. Statistical Analyses. Data were analyzed using StatDi-
rect Statistical software, version 2.6.5 (http://www.statsdirect
.com). 95% conﬁdence limits, Tukey-Kramer test was used
to compare the diﬀerence between means. In some exper-
iments, ANOVA followed by Dunnett’s test was used to
compare diﬀerenttreatmentswiththe controlgroup. A value
of P<. 05 was considered as signiﬁcant.
3. Results
3.1. Production and Characterization of Fluorescent VLP. In
order to determine whether Sf9 cells coinfected with bac-
ulovirusesexpressingrotavirusproteinswereabletogenerate
incomplete and complete VLP, samples were collected and
puriﬁed after infection and tested for viral proteins by SDS-
PAGE (Figure 1(a)) and Western Blot analysis (Figure 1(b)).
Anti-VP4 and anti-RF antibodies revealed an appropriate
production of proteins in both incomplete (GFP-VLP 2/6)
and complete (GFP-VLP 2/6/7/4) VLP. In addition, analysis
byelectronmicroscopywasperformedtoconﬁrmthecorrect
assemblyandstructureofVLP(Figure 1(c)).GFPconcentra-
tion was calculated using the same method described above
forVLP.ItisassumedthataVLPcontain120VP2molecules,
thus 120 molecules GFP [4]. Consequently, we estimated the
concentration of GFP at ∼8μg/VLP. The correct conforma-
tion of GFP from GFP:VP2 fusion protein within VLP was
conﬁrmed by direct analysis under ﬂuorescence microscopy
(Figure 2(a)). Spectroﬂuorometry was used to show that the
number of VLP particles; GFP ﬂuorescence was a linear
function of VLP concentration (Figure 2(b)). The relative
ﬂuorescence is in agreement with the generation of GFP-
associated VLP.
3.2.EntryofVLPintoCulturedEpithelialCells. Toexplorethe
capacity of VLP to deliver exogenous proteins to epithelial
cells, interaction experiments were ﬁrst performed between
trypsin-treatedVLPandculturedMA104epithelialcells.The
results obtained revealed that after a 20-minute exposure
period of trypsin-treated VLP with MA104 cells, only
complete VLP eﬃciently enter into cells, whereas incomplete
( d a t an o ts h o w n )a sw e l la st r y p s i nu n t r e a t e dV L Pd on o t
signiﬁcantly penetrate (Figure 3(a)). Internalization of VLP
was ﬁrst evaluated as the percentage of reduction of GFP-
VLP at the cell surface as measured by ﬂuorescence intensity
quantiﬁcation. After a 20-minute exposure period, only 50%
of the initial ﬂuorescence were recovered when trypsin-
treated VLP were used, whereas there was no signiﬁcant
decrease with untreated VLP (Figure 3(b)). In a second
experiment, we measured the amount of GFP that accumu-
lated within MA104 cell homogenates by using ELISA. As
shown in Figure 3(c), GFP was easily detectable after theJournal of Biomedicine and Biotechnology 5
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Figure 3: Eﬃciency of VLP internalization in intestinal epithelial cells in vitro. (a) Fluorescence microscopy of MA104 cells after 20-minute
exposure to complete GFP-VLP (green label) treated or not with trypsin. MA104 cell surface was labeled using WGA lectin (red label). A
representative image of 5 independent experiments is shown. (b) Internalization was quantiﬁed by measuring the GFP ﬂuorescence at the
cell surface using the built-in Leica software. Results are expressed as the amount of GFP ﬂuorescence (a.u.) at the cell surface as a function
of time. Results are means of 5 independent experiments. (c) Detection of GFP within cell homogenates using ELISA assay. GFP amounts
were determined immediately after the initial 20-minute interaction between cell and GFP-VLP (time 0) and then for the indicated times.
Samples were tested in triplicate in two independent experiments. Results are expressed as the mean absorbance value ± standard deviation
(sd).
initial 20-minute exposure period of VLP to MA104 cells. It
isimportanttonoteherethattheamountofimmunoreactive
GFP within cell homogenates showed a ∼75% drop of GFP,
six hours after contact with trypsin-treated VLP. This result
suggests that the GFP should probably be processed once
inside the cell.
3.3. Delivery of GFP by VLP into Intestinal Cells In Vivo.
Once it was established that complete VLP could deliver GFP
into MA104 cells, we next explored the capacity of these
particles to deliver GFP into intestinal cells in vivo. Confocal
analysis of intestinal samples from mice administered with
complete VLP resulted, as expected, in the detection of
GFP (green) that colocalized (yellow) with viral proteins
labeled with anti-RF rotavirus antibodies (red) in the ileum
(Figure 4(a)). Unexpectedly, we also observed the presence
of VLP within colonic epithelial cells in these in vivo
experiments (Figure 4(b)). To conﬁrm our observations,
viral proteins were quantiﬁed in mice ileum and colon
homogenates using ELISA. As expected from the above
experiments, we observed the presence of viral proteins
VP4, VP2, and VP6 in the ileum suggesting a signiﬁcant
entry of complete VLP, whereas incomplete VLP were unable
to signiﬁcantly penetrate the ileum (Figure 5). Using anti-
VP7 determination, we estimate that ∼42% (2.9 × 109 VLP)
entered in ileum and ∼30% (2.1 × 109VLP) in colon. More6 Journal of Biomedicine and Biotechnology
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Figure 4:CompleteVLPinternalizeinvivointheileum(a)andcolon(b).Frozensectionsofintestinalsamplesfrommiceadministeredwith
complete GFP-VLP (green) were labeled with anti-RF antibodies and Cy3-conjugated (red); FITC-lectin DSA was used as a positive control.
Tissue sections were analyzed by confocal microscopy. Overlay analysis shows that GFP colocalizes with viral proteins (yellow/orange). The
arrows indicate the VLP. Representative images of 3 experiments are shown. Scale bar 20 μm.
surprisingly a modest amount of VLP was recovered within
the colon and a very signiﬁcant amount of VP2 was detected
within the colon when incomplete VLP was used. It is worth
noting that using the protocol described above, the limit of
detection using these antibodies is of ∼9.3×109 to VP4, VP2
and VP6 and ∼1 × 109 to VP7.
3.4. Delivery of GFP by VLP into Intestinal Cells In Vivo
under Inﬂammatory Conditions. To determine whether our
approach could be used to deliver bio-active proteins into
intestinal cells under in vivo inﬂammatory conditions, we
assessed GFP delivery by VLP in a mouse model of intestinal
inﬂammation (TNBS model, see material and methods).
Groups of mice were slightly anesthetized and treated with
TNBS. Two days after, when the inﬂammation was estab-
lished, complete and incomplete VLP were administered,
tissue samples were collected and analyzed as indicated
in Figure 6(a). As expected, TNBS-treated mice presented
the common symptoms of colitis: hyperemia, ulcerations,
intestinal damage and assessed using the Wallace ScoreJournal of Biomedicine and Biotechnology 7
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Figure 5: Quantiﬁcation of viral proteins internalized in intestinal sections after VLP administration to living mice. The presence of VP2,
VP4, and VP6 rotavirus proteins in the ileum and the colon of mice administered with complete VLP (n =4) was evaluated by ELISA. Results
are expressed as absorbance units and are the mean ± sd. Dunnett’s test was used to compare treatments with the control group.
(Figure 6(b))andadiminutionincolonlength(Figure 6(c)).
None of these inﬂammation markers was inﬂuenced by
the presence of complete or incomplete VLP (Figure 6(b)).
Once inﬂammation was conﬁrmed in TNBS treated mice,
we evaluated the ability of complete and incomplete VLP
to transfer the reporter protein by measuring GFP amounts
in gut homogenates using ELISA. The results revealed the
presence of signiﬁcant amounts of GFP and viral proteins
in colon samples of both TNBS-treated and normal mice
(Figures 7(a) and 7(b)). In contrast, whereas viral proteins
were detected (Figure 7(c)), we were unable to detect signif-
icant amounts of GFP within the ileum. The current study
indicated that GFP-VLP entered both the ileum and the
colon and that the reporter protein was detectable in normal
and inﬂamed colon but not in the ileum.
4. Discussion
In this work, we show that nonreplicative trypsin-treated
VLP do penetrate into cultured cells and, when given
intragastrically to living mice, can also enter into both
normal and inﬂamed intestinal epithelium. Our results also
show that VLP can transport biomolecules such as GFP to
speciﬁc sites both in vivo and in vitro. This represents a
potential original new nanoparticle system for delivering
bioactive molecules directly into intestinal cells.
Our in vitro experiments using epithelial MA104 cells
showaneﬃcientinternalization(∼50%)oftrypsin-activated
complete VLP after only 20 minutes of interaction. These
observationsareconsistentwithpreviouslyreportedﬁndings
and conﬁrm that the cleavage of the rotavirus spike protein
VP4 is a prerequisite for cellular internalization [4, 16].
Accordingwithpreviouslyreported ﬁndings,weobserve that
absenceofVP4andVP7doesnotmodifycellattachment[4].
However, several investigations have already demonstrated
the key role of the tryptic cleavage of VP4 for cellular entry
[16, 17, 21–24]. Thus, according to these observations, our
results conﬁrm that nonreplicative VLP display attachment
and entry properties very similar to those of authentic
rotavirus.
After administration of complete GFP-VLP to mice, and
as expected given the homology with infectious rotavirus, we
observed the delivery of complete but not of incomplete VLP
to the ileum, the natural target of this virus by ﬂuorescence
microscopy and ELISA detection of viral proteins within cell
homogenates. In addition, it is worth noting that eﬃcacy of
bovine Rotavirus heterologous infection has not been well
studied. Recently, Istrate C and collaborators report for the
ﬁrsttimethatabovineRotavirusstrainiscapableofinfecting8 Journal of Biomedicine and Biotechnology
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Figure 6: TNBS-induced colitis in the mouse model. (a) Scheme of the experimental protocol used for the induction of colitis in mice and
time of complete or incomplete VLP administration, buﬀer administration, and sacriﬁce. (b) Colonic macroscopic damage according to
the criteria of Wallace of TNBS-treated animals (n = 4). (c) Comparison of colon length between control and TNBS-treated mice (n = 4).
Tukey-Kramer test was used to compare the diﬀerence between means. Results are expressed as the means ± sd.
murine bmDC in vitro [25]. Likewise Guerin-Danan et al.
reported the capacity of simian SA11 to infect rats [26]. Our
results strongly suggest that VLP enter ileum through the
classicalroutethatstrictlydependsonthepresenceofcleaved
VP4 and VP7 capsid proteins. Thus provide evidence of
“in vivo” heterologous Rotavirus pseudoinfection. However,
despite this obvious entry process of complete VLP, we were
unable to detect GFP within the ileum by ELISA. During the
in vivo experiments, the time between VLP administration
and sample processing was at least 4 hours, that is, the time
after which the large majority of GFP has disappeared in
the in vitro experiments. The absence of detection of GFP
within the ileum is likely due to the fact that the protein
was already delivered to an intracellular compartment where
it suﬀers an alteration either in the conformation or in the
concentration and not only due to a subcellular localization
where ﬂuorescence can be quenched, as proposed earlier
[4]. In the meantime, it should be emphasized that viral
structural proteins that have also entered within mice ileum
are still signiﬁcantly expressed in the tissue. This means
that the fate of each particular protein that has entered the
ileum should be speciﬁc. Further development of our work
have to analyze this point carefully in order to add targeting
information to a putative vectorized therapeutic protein
allowing to escape this denaturation/degradation event.
Astonishingly, the results indicate that, in the colon, a
signiﬁcant entry of complete VLP happens and even more
that an uptake of incomplete VLP may also be observed,
as assessed by the detection of the internal capsid protein
VP2 within colon tissue homogenate. In addition, GFP was
eﬃciently delivered to colonic tissues either with complete or
incomplete VLP-GFP. Entry of a small amount of complete
VLP within the colon results in a very eﬃcient delivery
of the reporter protein. Comparison of these data with
those observed in the ileum leads to the suggestion that
complete VLP enter the colon through an alternative route,
driving the VLP to an intracellular compartment where no
subsequent GFP modiﬁcations can occur. Such a hypothesis
is highly plausible given the cell populations present in
the colon as compared to the ileum. In this regard, it hasJournal of Biomedicine and Biotechnology 9
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Figure 7: Complete or incomplete VLP delivery to the normal or inﬂamed gut. Delivery of GFP (a) and viral proteins (b) to the colon
and of viral proteins to the ileum (c) from healthy and TNBS-treated mice (n = 4) was evaluated by ELISA assays. Results are expressed as
absorbance units and are the mean ± sd of three experiments. Dunnett’s test was used to compare treatments with the control group.
already been shown that complete VLP, but not incomplete
VLP were able to enter in dendritic cells “in vitro” [4].
In addition, previously reports have shown that rotavirus
preferentially targeted to absorbing intestinal cells rather
than Peyer’s Patches in suckling rats [26]. Although the
precise identiﬁcation of this compartment and/or the cell
types implied remains to be determined, our results show
that only complete VLP are able to enter into the ileum. This
work represents the ﬁrst study of VLP interaction “in vivo”
and clearly demonstrates that complete VLP represent a new
eﬃcient tool to deliver a biomolecules to the colon.
In the case of incomplete VLP, the mechanism of GFP
transfer into the colon appears diﬀerent, since our results
indicate that only VP2 (and GFP) can be detected in these
conditions within the colonic tissue. A possible explanation
for these results may be that VP6 into incomplete VLP
are much more accessible to intraluminal degradation than
complete VLP; consequently, VP2:GFP enters alone within
colonic cells. If this is the case, VP2 may represent an inter-
esting vector protein.
Finally, one of our goals was to demonstrate that VLP
may be used in both healthy and inﬂamed intestinal tissues.
Thanks to the TNBS model, we were able to generate a true
colitis and to check the capacity of VLP to transfer GFP into
both normal and inﬂamed mice colons. Our results clearly
indicate that GFP was eﬃciently transferred within the colon
in the two situations, thus opening the possibility to further
elaborate this new and original delivery vector with the aim
to propose innovative treatments for IBD.
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